Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study

OBJECTIVE: Patients with Lennox‐Gastaut syndrome (LGS) who completed 1 of 2 randomized, double‐blind, placebo‐controlled trials of add‐on cannabidiol (CBD) (GWPCARE3, NCT02224560 or GWPCARE4, NCT02224690) were invited to enroll in an open‐label extension (OLE) study evaluating the long‐term safety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiele, Elizabeth, Marsh, Eric, Mazurkiewicz‐Beldzinska, Maria, Halford, Jonathan J., Gunning, Boudewijn, Devinsky, Orrin, Checketts, Daniel, Roberts, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850399/
https://www.ncbi.nlm.nih.gov/pubmed/30740695
http://dx.doi.org/10.1111/epi.14670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850399/
https://www.ncbi.nlm.nih.gov/pubmed/30740695
http://dx.doi.org/10.1111/epi.14670

Ejemplares similares